Skip to main content

SuperMicrobiologists

Pharma: Why Are Rapid Microbiological Methods Still Rarely Used in Routine Testing?

Published on 25 August 2026 6 min





A few days ago, I took part in a live discussion with the QP Pharma team about Rapid Microbiological Methods (RMMs).

We talked about the different technologies available, their potential applications, the expected benefits, time savings, faster product release, reduced waiting times… in short, everything that makes these methods attractive on paper.

Then, at one point, someone made a comment that really caught my attention:

“If all these technologies are so great, why do we almost never see them used routinely in laboratories?”

As a former application specialist for rapid microbiological methods, I have to admit that this question feels a little like a personal failure.

But to be fair… they are not entirely wrong.

Because yes, the technologies exist. And yes, they offer many advantages: faster results, automation, improved data integrity, and more.

So why is adoption still so limited?

Here are a few thoughts. They are not absolute truths, just personal observations based on what I have seen, experienced, and learned in the field.


Discover the Top 4 Rapid Micro Methods

We asked the SuperMicrobiologists in a big survey.
Here’s what they said.

Validating a Rapid Method Is Complex

The first challenge is validation.

Implementing a rapid microbiological method is not as simple as buying an instrument, attending a training session, and starting to test samples.

First, you must demonstrate that the alternative method provides results comparable to the traditional (compendial) method.

To do this, you need to design a validation protocol (the first challenge) and generate robust data (the second challenge).

There are, of course, documents available to guide this process, including the European Pharmacopoeia, the United States Pharmacopeia, and the recently published PDA Technical Report 33.

Even so, in practice, designing and executing a validation study remains a difficult exercise.

Preparing Microbial Strains Is Often a Critical Step

One of the most underestimated challenges is strain preparation.

To validate a rapid method, laboratories often need to work with quantified microbial suspensions at very low concentrations, such as 1, 5, or 10 cells.

These strains are used to challenge the alternative method and compare its performance with the traditional method.

And from experience, I can tell you that preparing these suspensions correctly is not always easy.

Accurately calibrating microorganisms can be difficult. If a dilution error occurs, the entire series of tests may have to be repeated.

Another challenge is that a test may work one day and fail the next. It is tempting to blame the alternative method, when the issue may actually come from the strain itself, its physiological state, the way it was prepared, or the way it was stored.

In my opinion, this is an area where greater standardization will eventually be needed. The use of ready-to-use calibrated strains should help.

RMM Validation Is a Skill in Its Own Right

In many cases, alternative method validation is assigned to the Quality Control laboratory.

This seems logical since the QC laboratory will ultimately use the method.

However, validating an alternative method requires a different set of skills than routine microbiological testing.

I am not saying that QC microbiologists cannot do it. Quite the opposite.

But validation requires time, dedicated training, a structured methodology, availability, and sometimes a true project team.

In my experience, the projects that succeeded were those where a dedicated team had been trained, supported, and freed from routine laboratory activities to focus specifically on validation.

When validation becomes just another task added between daily priorities and urgent requests, it is often pushed aside. Timelines become longer, teams lose motivation, and the first disappointing results can easily become an excuse to stop the project altogether.

Statistics Can Be Intimidating

Another important challenge is statistical analysis.

Many of us chose microbiology because we preferred biology over mathematics… and therefore over statistics!

Unfortunately, statistics quickly become unavoidable when validating an alternative method.

Method comparisons, equivalence studies, repeatability, reproducibility, limits of detection, limits of quantification, confidence intervals, ANOVA, Xi values (pronounced “Kai”)… the list can be intimidating.

My personal recommendation is simple: work with a statistician.

After all, everyone has their own area of expertise.


Discover the Top 4 QC Strains for Pharma

We asked the SuperMicrobiologists in a big survey.
Here’s what they said.

A Rapid Method… But for What Purpose?

I have seen situations where a laboratory validated a rapid sterility test.

Great, the result is available in hours or days instead of 14 days.

But regardless of the microbiology result, the batch still required an average of 21 days of documentation review before release.

In that situation, was a rapid microbiological method really the priority?

To avoid asking these questions after completing validation, the need must first be identified at the company level, not only within the microbiology laboratory.

Where is microbiology truly creating a bottleneck?

  • Is it delaying batch release?
  • Is it tying up inventory?
  • Is it slowing production decisions?
  • Is it delaying investigations?
  • Is it creating business costs or risks?


The user requirement specification should be based on the business need, not on the capabilities of the technology.

Build the User Requirement Specification with All Stakeholders

A rapid method does not only affect the microbiology laboratory.

It may also impact:

  • Quality Assurance
  • Sterility Assurance
  • Manufacturing
  • Supply Chain
  • Maintenance
  • Finance


And we should never forget IT.

Today, almost every technology includes software, a computer, or network connectivity. If IT becomes involved too late, significant roadblocks can appear.

The same is true for finance.

The return on investment of a rapid method can be difficult to demonstrate when viewed only from the laboratory perspective.

However, it often becomes much clearer when evaluated at the company level through faster batch release, reduced inventory, improved responsiveness, reduced risk, and better process efficiency.

Bring all stakeholders together from the very beginning of the project, starting with the creation of the user requirement specification.

Conclusion

Rapid microbiological methods are not absent from pharmaceutical laboratories because they do not work.

They are still underused because successful adoption requires much more than a purchase order.

It requires a clear strategy, a well-defined business need, a solid user requirement specification, a dedicated project team, validation expertise, and a company-wide understanding of the expected benefits.

And while validation is certainly not easy, it is far from impossible.

I would be very interested to hear your thoughts:

In your laboratory, what is the biggest barrier to adopting rapid microbiological methods?

Leave a Reply

Your email address will not be published. Required fields are marked *